Dianthus Therapeutics’ (DNTH) “Outperform” Rating Reiterated at Raymond James Financial

Raymond James Financial restated their outperform rating on shares of Dianthus Therapeutics (NASDAQ:DNTH) in a research note released on Tuesday morning,Benzinga reports. The firm currently has a $63.00 price target on the stock, up from their prior price target of $56.00.

Several other equities research analysts have also issued reports on the stock. Guggenheim raised their price target on shares of Dianthus Therapeutics from $92.00 to $100.00 and gave the stock a “buy” rating in a research note on Tuesday. Wedbush lifted their price objective on shares of Dianthus Therapeutics from $34.00 to $42.00 and gave the company an “outperform” rating in a research note on Thursday, August 21st. Robert W. Baird raised their price target on shares of Dianthus Therapeutics from $50.00 to $67.00 and gave the company an “outperform” rating in a report on Tuesday. William Blair began coverage on shares of Dianthus Therapeutics in a report on Wednesday, July 2nd. They issued an “outperform” rating for the company. Finally, HC Wainwright reissued a “buy” rating and issued a $40.00 price target on shares of Dianthus Therapeutics in a report on Monday. Eight research analysts have rated the stock with a Buy rating, According to MarketBeat, the company has an average rating of “Buy” and a consensus price target of $60.67.

Dianthus Therapeutics Trading Down 0.1%

Shares of Dianthus Therapeutics stock opened at $37.86 on Tuesday. The business has a 50-day moving average price of $22.65 and a two-hundred day moving average price of $20.43. Dianthus Therapeutics has a 1-year low of $13.36 and a 1-year high of $38.59. The company has a market cap of $1.22 billion, a P/E ratio of -11.65 and a beta of 1.46.

Dianthus Therapeutics (NASDAQ:DNTH) last released its quarterly earnings data on Thursday, August 7th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.02). Dianthus Therapeutics had a negative return on equity of 34.72% and a negative net margin of 2,364.56%.The company had revenue of $0.19 million for the quarter, compared to the consensus estimate of $0.87 million. Equities research analysts forecast that Dianthus Therapeutics will post -2.61 EPS for the current fiscal year.

Insiders Place Their Bets

In other Dianthus Therapeutics news, CFO Ryan Savitz sold 20,000 shares of the company’s stock in a transaction dated Tuesday, September 9th. The shares were sold at an average price of $35.00, for a total value of $700,000.00. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Company insiders own 8.15% of the company’s stock.

Institutional Trading of Dianthus Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of DNTH. Raymond James Financial Inc. purchased a new position in shares of Dianthus Therapeutics in the 2nd quarter worth $27,000. US Bancorp DE lifted its holdings in shares of Dianthus Therapeutics by 2,013.3% in the 1st quarter. US Bancorp DE now owns 1,585 shares of the company’s stock worth $29,000 after acquiring an additional 1,510 shares during the last quarter. BNP Paribas Financial Markets bought a new stake in shares of Dianthus Therapeutics in the 4th quarter worth about $59,000. GAMMA Investing LLC lifted its holdings in Dianthus Therapeutics by 3,030.6% during the 1st quarter. GAMMA Investing LLC now owns 3,882 shares of the company’s stock valued at $70,000 after buying an additional 3,758 shares in the last quarter. Finally, Tower Research Capital LLC TRC lifted its holdings in Dianthus Therapeutics by 330.7% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,320 shares of the company’s stock valued at $80,000 after buying an additional 3,317 shares in the last quarter. 47.53% of the stock is currently owned by institutional investors.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.